Economic Assessment of Delaying Insulin Treatment Through The Use of Newer Anti-Diabetic Agents, Dapagliflozin (Forxiga®) And Exenatide (Bydureon®), Both As Add-On To Metformin; A Cost-Effectiveness Analysis From A Uk Nhs Perspective
Abstract
Authors
M. Charokopou H. Vioix B.G. Verheggen D. Maddocks T. Bratt D. Franks